Oxford Immunotec Global PLC and Qiagen NV settled a lawsuit regarding alleged patent infringement of Qiagen products.
The suit, filed in U.S. District Court for the District of Massachusetts in Boston, covered the Dutch company's QuantiFeron-TB gold and QuantiFeron-TB Gold Plus products.
U.K.-based Oxford granted Qiagen a royalty-free, nonexclusive license that extends to all current and future customers of the two Qiagen products in exchange for a one-time lump sum of $27.5 million.
Under the settlement, all pending claims between Oxford and Qiagen and the co-defendants were resolved. None of the parties admitted to any wrongdoing.
QuantiFeron-TB Gold is a diagnostic aid that detects infection caused by Mycobacterium tuberculosis, a type of bacteria that causes tuberculosis.